Recent developments include YD Bio's strategic partnership with YC Biotech to enhance regulatory capabilities in the U.S. and Asia, a letter of intent to acquire Safe Save Medical to expand immunocell therapy leadership, and an outlined ambitious roadmap for 2026 following a transformative 2025. Market commentary has noted the company's shares as oversold.

• YD Bio USA entered a Master Strategic Alliance Agreement with YC Biotech to establish a Taiwan-U.S. dual-core regulatory platform covering FDA submissions and regulatory liaison [S2].
• YD Bio signed a letter of intent to acquire Safe Save Medical, aiming to expand its leadership in immunocell therapy [N3].
• The company outlined an ambitious 2026 roadmap following a transformative 2025, focusing on advancing clinical, regulatory, and commercial initiatives [N4].
• Market commentary described YD Bio shares as oversold, reflecting recent trading dynamics [N1].

YD Bio's extensive suite of solutions across oncology diagnostics, ophthalmology, and nutritional products addresses large and underserved markets with multi-billion-dollar potential. Strategic partnerships with established pharmaceutical companies and licensing agreements enhance credibility and market access. The company's regulatory advancements, including FDA filings and manufacturing readiness for cell therapy products, support clinical and commercial development. Recent capital raises provide liquidity to fund expansion initiatives, including acquisitions to broaden immunocell therapy leadership. The company's founder-led management team brings deep expertise in biotech and finance, supporting execution of growth strategies.

YD Bio has incurred significant recurring losses and negative cash flows from operations, raising substantial doubt about its ability to continue as a going concern without additional financing. The company faces concentration risks with a few customers and suppliers accounting for large portions of revenue and purchases, which may impact operational stability. Foreign currency exchange risk due to revenues and costs denominated in NTD and reporting in USD adds financial uncertainty. Execution of expansion plans requires substantial increases in production capacity, skilled labor, and capital expenditures, which may strain resources. Regulatory and market uncertainties may delay or impede clinical and commercial progress.

YD Bio's competitive advantages stem from its proprietary technology supported by multi-decade exclusive licensing agreements and a robust intellectual property portfolio. Strategic partnerships with global pharmaceutical companies and licensing collaborations provide validation and potential growth avenues. The company's regulatory progress, including FDA Drug Master Files for its cell therapy platforms, establishes a reusable regulatory framework that may reduce program risk. These factors collectively contribute to barriers to entry and differentiation in large, underserved markets with significant growth potential.

• Recurring Losses and Going Concern: YD Bio has reported net losses for multiple years and has substantial doubt about its ability to continue as a going concern without additional financing.
• Customer and Supplier Concentration: A limited number of customers and suppliers account for significant portions of revenue and purchases, posing risks to revenue stability and supply chain.
• Foreign Currency Exchange Risk: Revenues and costs are denominated in New Taiwan Dollar while financial reporting is in USD, exposing the company to currency fluctuations.
• Execution and Expansion Risks: Expansion plans require increased production capacity, skilled labor, and capital expenditures, which may be challenging to execute effectively.
• Regulatory and Market Uncertainties: Advancement of clinical and commercial initiatives depends on regulatory approvals and market conditions, which carry inherent uncertainties.

• YD Bio Ltd operates in biotechnology and medical-related products, including ophthalmology cellular drug development, pancreatic and breast cancer blood tests, and nutritional product sales.
• The company has strategic partnerships with global pharmaceutical companies such as Novartis and Alcon, and licensing partnerships with EG BioMed and 3D Global for cancer detection and eye disorder treatments respectively.
• YD Bio has proprietary technology supported by multi-decade exclusive licensing agreements and an intellectual property portfolio.
• The company serves large and underserved markets with projected multi-billion-dollar global market sizes over the next decade.
• YD Bio is a clinical testing drug supplier and has a founder-led management team with expertise in drug development, health product development, pharmacy channel development, and financial management.
• The company operates primarily in Taiwan and the United States, with product sales in Taiwan including drugs, medical and related products, nutritional products, and supplements, and contact lens sales in the U.S.
• YD Bio USA, a subsidiary, entered a strategic partnership with YC Biotech to create a Taiwan-U.S. dual-core regulatory platform covering FDA submissions and regulatory liaison.
• The company has advanced its cell therapy and exosome platform with completed manufacturing and regulatory de-risking, including FDA Drug Master Files for Limbal Stem Cells and exosomes.
• YD Bio's 2025 financials show revenue of approximately $597K, net loss of about $8.3 million, and negative EPS of -$0.12 per share.
• As of December 31, 2025, YD Bio held $6.0 million in cash and cash equivalents, with a current ratio of 5.88 and a cash ratio of 3.66, indicating liquidity.
• The company has incurred recurring losses and negative cash flows from operations over recent years and has raised capital through private equity offerings and a PIPE financing of $13.2 million in 2025.
• YD Bio plans capital expenditures primarily related to real estate acquisition and production facilities, with operating expenses including increased research and development and general administrative costs.
• The company faces concentration risks with significant purchases from a supplier controlled by the CEO and customer concentration with a few customers accounting for a large portion of sales.
• YD Bio's business expansion involves increased costs for skilled labor, production capacity, business development, IT, marketing, and back-office support.
• The company is subject to foreign currency exchange risk due to revenues and costs denominated in New Taiwan Dollar (NTD) and reporting in USD.
• YD Bio is classified as an emerging growth company and files annual reports on Form 20-F.
• The company has disclosed no governmental restrictions on capital remittance or exchange controls in the Cayman Islands, where it is incorporated.
• YD Bio's 2026 operational plans include advancing selected assets from validation toward expanded clinical, regulatory, and commercial execution subject to regulatory and market conditions.
• The company has a single reportable segment covering sales of medical devices, research and development in cancer detection, and contact lens sales.
• YD Bio's 2025 revenues were primarily generated in Taiwan, with a smaller portion from the U.S. contact lens market.
• The company has a significant accumulated deficit and substantial doubt about its ability to continue as a going concern without additional financing.
• YD Bio's recent news includes signing a letter of intent to acquire Safe Save Medical to expand immunocell therapy leadership and outlining an ambitious 2026 roadmap following a transformative 2025.
• YD Bio shares have been described as oversold in recent market commentary.
• The company has entered into a strategic partnership with YC Biotech to enhance regulatory capabilities in the U.S. and Asia.